IGF-1 LR3 Reconstitution Calculator

No. It has no regulatory approval for physique- or performance-related indications, the contexts in which it is actually used, and is distributed as an unregulated "research compound". Supply-chain composition is unverified: a His-tagged variant of Long-R3-IGF-I has been detected in a black-market product. Purchasing means an unapproved drug with unknown purity and sterility (observational).

Subcutaneous injection is the standard community route (community protocol). Oral dosing is not systemically viable: in neonatal calves, oral Long-R3-IGF-I at 50 μg/kg/day for 7 days produced no rise in plasma levels, whereas subcutaneous dosing did. In rats, oral LR3IGF-I is preferentially delivered to intestinal tissue compared with native IGF-I, consistent with gut-local rather than systemic action. Experimental efficacy data used continuous intravenous infusion.

Animal data span 120 μg/day (~340 μg/kg) infused in guinea pigs, 50 μg/kg/day subcutaneously in calves, and 180 μg/kg/day infused in pigs, a dose that reduced growth. Community physique protocols run far lower in absolute terms: roughly 20–80 μg once daily subcutaneously for 4–6 weeks (community protocol). Online dosing patterns vary widely and are unvalidated against any human pharmacokinetic data.

Yes, hypoglycemia is a recognized risk. In fetal sheep, LR3 lowered plasma glucose and insulin and blunted glucose-stimulated insulin secretion, with a 1-week infusion producing a persistent islet defect; even a 90-minute infusion cut clamp-stimulated insulin by 66%. In pigs, plasma insulin fell although glucose remained stable. IGF-1 receptor activation overlaps insulin signaling (mechanistic). Monitor blood glucose, especially fasted or around training (community protocol). Pregnancy: no human data exist; in fetal sheep LR3 perturbed fetal insulin/glucose homeostasis and failed to improve growth in growth-restricted fetuses.

Human evidence: none. Animal data are mixed and mostly negative for hypertrophy: fetal sheep showed organ growth and muscle-cell (myoblast) proliferation but no hindlimb-muscle mass gain; rats with volumetric muscle loss gained muscle weight only at high dose, with no strength improvement; cachectic mice preserved some muscle but at the cost of accelerated tumor growth; finisher pigs lost average daily gain; guinea pigs gained organ weight without total body growth. Lean-mass claims rest on anecdotes, not data.

Plausible but unproven in humans. The IGF-1 receptor is overexpressed on many cancers and is implicated in metastasis and apoptosis resistance; in a mouse cachexia model, LR3 IGF-I treatment accelerated tumor growth. Near-absent IGFBP binding raises free, receptor-active IGF-1, increasing mitogenic signaling potential (mechanistic). The clinical literature flags "biologically plausible but unproven mitogenic concerns". Avoid with personal or family history of IGF-sensitive cancers (breast, prostate, colorectal).

No human safety duration is established. Animal exposures were mostly 1 week (sheep, calves, pigs, guinea pigs); a 7-month intranasal mouse study showed no cognitive worsening but no cognitive benefit either. Repeated LR3 suppresses the endogenous GH–IGF axis, lower growth hormone, IGF-I and IGFBP-3 in pigs, calves, and guinea pigs, so community practice limits cycles to ~4–6 weeks with an equal off-period (community protocol).

IGF-1 LR3 is prohibited in sport under WADA; intact long-R3-IGF-I is detectable in blood by liquid chromatography–high-resolution mass spectrometry doping control. Black-market products may carry detectable tags such as His-tags. Athletes subject to testing should assume blood-detection windows in the days-to-weeks range (community protocol).